Melanoma Clinical Trial
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Summary
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
Eligibility Criteria
Inclusion Criteria:
Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma rendered free of disease by surgical resection.
Patients are being offered adjuvant nivolumab or pembrolizumab therapy
Patient has not yet formally discussed their treatment options with their Medical Oncologist.
Age 18 or older.
Ability to speak and read English because we do not have the resources to translate materials into other languages.
Exclusion Criteria:
Patient not currently free of disease.
Candidate for adjuvant dabrafenib/trametinib therapy.
Patients who have received prior checkpoint inhibitor therapy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Basking Ridge New Jersey, 07920, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
How clear is this clinincal trial information?